Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Period	Debt/Equity
2015-12-31	0.22
2016-12-31	0.73
2017-12-31	0.64
2018-12-31	0.25
2019-12-31	0.39
2020-12-31	1.14
2021-12-31	0.11
2022-12-31	0.13
2023-12-31	0.16
2024-12-31	0.08

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AGIO	$33.72	-3.95%	0.70M
3
4
5

Agios Pharmaceuticals Inc. (AGIO) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Agios Pharmaceuticals Inc. Data in Excel

More AGIO Financial Data